Odyssey Therapeutics, Inc. Common Stock (ODTX) Stock
Key stats
- Market cap
- $1.01B
- Price / Earnings ratio
- -6.5x
- EPS (TTM)
- -$48.93
- Volume
- Loading
- 52-week high
- $29.05
- 52-week low
- $15.10
Source: third-party data provider, as of November 13, 2026
Compare with ODTX
Recent news

Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts
Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts
ODTX

Odyssey Therapeutics Hits $900M Valuation In Nasdaq Debut, Stock Climbs 13% Before Diving Lower
Odyssey Therapeutics Hits $900M Valuation In Nasdaq Debut, Stock Climbs 13% Before Diving Lower
ODTX

Biotech firm Odyssey valued at $899.9 million as shares rises in Nasdaq debut
Biotech firm Odyssey valued at $899.9 million as shares rises in Nasdaq debut
ODTX

Biotech firm Odyssey raises $279 million in upsized US IPO
Biotech firm Odyssey raises $279 million in upsized US IPO
ODTX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 56.65
- MACD 12/26/9
- -0.02
- EMA 9 of MACD
- -0.25
- MACD histogram
- 0.23
- SMA 50
- $20.91
- Price above SMA 50
- EMA 50
- $20.15
- Price above EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts
Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts
ODTX

Odyssey Therapeutics Hits $900M Valuation In Nasdaq Debut, Stock Climbs 13% Before Diving Lower
Odyssey Therapeutics Hits $900M Valuation In Nasdaq Debut, Stock Climbs 13% Before Diving Lower
ODTX

Biotech firm Odyssey valued at $899.9 million as shares rises in Nasdaq debut
Biotech firm Odyssey valued at $899.9 million as shares rises in Nasdaq debut
ODTX

Biotech firm Odyssey raises $279 million in upsized US IPO
Biotech firm Odyssey raises $279 million in upsized US IPO
ODTX

Biotech firm Odyssey targets $810 million in valuation in US IPO
Biotech firm Odyssey targets $810 million in valuation in US IPO
ODTX

Odyssey Therapeutics Appoints H. Martin Seidel, Ph.D.
Odyssey Therapeutics Appoints H. Martin Seidel, Ph.D.
ODTX

Odyssey Therapeutics Appoints Jolie M. Siegel as Executive Vice President, General Counsel
Odyssey Therapeutics Appoints Jolie M. Siegel as Executive Vice President, General Counsel
ODTX

Odyssey Therapeutics Appoints Dennis Dean, Ph.D., as Executive Vice President, Head of Non-Clinical Development
Odyssey Therapeutics Appoints Dennis Dean, Ph.D., as Executive Vice President, Head of Non-Clinical Development
ODTX

Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to Its Board of Directors
Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to Its Board of Directors
ODTX

Odyssey Therapeutics Announces Oversubscribed $213 Million Series D Financing to Advance Clinical Pipeline for Autoimmune Diseases
Odyssey Therapeutics Announces Oversubscribed $213 Million Series D Financing to Advance Clinical Pipeline for Autoimmune Diseases
ODTX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Odyssey Therapeutics, Inc. Common Stock
Odyssey Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and inflammatory diseases. The company is led by an experienced team of drug discovery and development experts and leverages capabilities in immunobiology, medicinal and computational chemistry, protein biochemistry, structural biology, genetics, and pharmacology to identify and target key signaling pathways that drive disease.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Gary D. Glick Ph.D. | Founder, President, CEO & Director | 1962 |
| Mr. Jason Haas M.B.A. | Chief Financial Officer | 1968 |
| Mr. Collin Todd | Senior Vice President of Strategy & Business Development | 1992 |
| Prof. Eicke Latz M.D., Ph.D. | Scientific Co-Founder | — |
| Dr. Kim Lewis Ph.D. | Scientific Co-Founder | — |
| Dr. Felix Meissner Ph.D. | Scientific Co-Founder | — |
| Dr. Florian.I Schmidt Ph.D. | Scientific Co-Founder | — |
| Ms. Jolie M. Siegel J.D. | Executive VP, General Counsel & Secretary | 1977 |
| Dr. Natalie Dales Ph.D. | Chief of Research Operations & Portfolio Strategy | 1970 |
| Dr. Joseph McDonald Ph.D. | Chief Data Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 56.65
- MACD 12/26/9
- -0.02
- EMA 9 of MACD
- -0.25
- MACD histogram
- 0.23
- SMA 50
- $20.91
- Price above SMA 50
- EMA 50
- $20.15
- Price above EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $27.00
- Average
- $38.25
- High
- $44.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +3.6 | +10.3 | +14.0 | +35.2 | -9.3 | -4.3 | +7.5 |



